Acticor Biotech is a clinical-stage biotechnology company developing glenzocimab (ACT017), a humanized antibody fragment that targets platelet glycoprotein VI (GPVI) to inhibit thrombus growth while limiting bleeding risk. Preclinical and early evidence of antithrombotic efficacy and safety have been demonstrated ex vivo and in vivo. The company’s lead program is the Phase II ACTIMIS trial in acute ischemic stroke, which it plans to expand into the US following an encouraging pre-IND consultation with the FDA and an intended IND filing in the coming months. Acticor recently completed its Series B financing, bringing the round to €22.3M after an additional €7M equity raise. Concurrent with the financing close, Acticor acquired 100% of AVCare and secured worldwide sub-licensing rights from SATT Ouest Valorisation to develop and exploit a stroke blood biomarker. Leila Nicolas of Go Capital will join Acticor’s board as part of the transaction. Acticor Biotech is a clinical-stage biotechnology company spun off from INSERM focused on developing therapies for acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Its lead candidate, ACT017, is a humanized antibody fragment (Fab) that targets platelet glycoprotein VI (GPVI) to inhibit thrombus growth while limiting bleeding risk. Evidence of ACT017's antithrombotic efficacy and safety of GPVI inhibition has been demonstrated ex vivo and in vivo. The company plans to advance ACT017 into its first Phase II clinical trial in acute ischemic stroke. The recent Series B financing will enable this Phase II and support additional clinical development in other indications. Acticor is headquartered in Paris and builds on research from its founders at INSERM and Paris-Sud University. Acticor Biotech is developing ACT017, a humanized fragment of a monoclonal antibody that binds the platelet receptor GPVI and inhibits platelet adhesion and aggregation on collagen and polymerized fibrin. The company is focused on treatments for the acute phase of thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor closed a €1.7m equity financing and also secured €2.2m in grants from the Concours Mondial de l’Innovation, for a total of €3.9m. The proceeds are intended to strengthen cash position in preparation for the company’s first clinical Phase II for ACT017. Acticor was founded in 2013 as a spin-off of Inserm and is led by Dr Gilles Avenard, and is based in Paris, France. Acticor Biotech is developing ACT‑017, a first‑in‑class anti‑thrombotic candidate that inhibits glycoprotein VI to prevent clot growth during ischemic strokes. ACT‑017 is intended for use alone or in combination with Alteplase® and aims to be safe from bleeding risk. In vitro and in vivo testing have confirmed previously published results and suggest the candidate could be administered shortly after symptoms appear. The company completed a €1.4 million capital increase to fund continued pre‑clinical development and to produce initial batches of ACT‑017. Management frames the emergency treatment of ischemic stroke as a major unmet need in Europe, affecting over 600,000 patients per year. The round was organized in part via the Anaxago crowdfunding platform, reflecting investor interest in the company’s stroke‑treatment development.

Total raised

$29M

Funding rounds

4

Latest round

Series B

Latest activity

Nov 2019